Analysis of first recurrence and survival in patients with stage I non–small cell lung cancer treated with surgical resection or stereotactic radiation therapy  by Crabtree, Traves D. et al.
Crabtree et al General Thoracic SurgeryAnalysis of first recurrence and survival in patients with stage
I non–small cell lung cancer treated with surgical resection
or stereotactic radiation therapyTraves D. Crabtree, MD,a Varun Puri, MD,a Clifford Robinson, MD,c Jeffrey Bradley, MD,c
Stephen Broderick, MD,a G. Alexander Patterson, MD,a Jingxia Liu, PhD,b Joanne F. Musick, RN,a
Jennifer M. Bell, BSN,a Michael Yang, BS,a and Bryan F. Meyers, MD, MPHaFrom th
Biost
of M
Researc
Instit
Natio
of He
Disclos
for E
for E
consu
comm
The con
sent t
Read at
gery,
Receive
publi
Address
Towe
6311
0022-52
Copyrig
http://dx
G
T
SObjectives: Comparative studies of survival between stereotactic body radiation therapy (SBRT) and surgery
have been limited by lack of comparisons of recurrence patterns between matched cohorts in nonsmall cell
lung cancer (NSCLC).
Methods: All patients undergoing treatment with surgery or SBRT for clinical stage I NSCLC between June
2004 and December 2010 were reviewed. Age, tumor characteristics, comorbidity score, pulmonary function,
overall survival (OS), disease-free survival (DFS), and recurrence data were collected and propensity matching
performed.
Results: Themean age for surgery (n¼ 458) was 65.8 10.5 versus 74.4 9.4 for SBRT (n¼ 151) (P<.0001).
For the entire surgical cohort, 3-year OS was 78% and DFS was 72%. For the entire SBRT cohort, 3-year OS
was 47% and DFS was 42%. The overall local recurrence rate for surgery was 2.6%. The overall local
recurrence rate for SBRT was 10.7%. A propensity-matched comparison based on age, tumor size, Adult
Comorbidity Evaluation comorbidity score, forced expiratory volume in the first second of expiration, and tumor
location resulted in 56 matched pairs. The 3-year OS was 52% versus 68% for SBRT and surgery (P ¼ .05);
DFS was 47% versus 65% (P ¼ .01). At 3 years, local recurrence-free survival was 90% versus 92% for
SBRT and surgery (P ¼ .07).
Conclusions: Although surgical resection seems to result in better OS and DFS versus SBRT, matching these
disparate cohorts of patients remains challenging. Participation in clinical trials is essential to define the
indications and relative efficacy of surgery and radiation therapy in a high-risk population with stage I NSCLC.
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The Journal of Thoracic and CarStereotactic body radiation therapy (SBRT) has become the
primary treatment of choice for inoperable patients with
peripheral stage I lung cancer. Although the role of radiofre-
quency ablation has yet to be defined for stage I lung cancer,
single-center studies and a prospective trial of SBRT have
consistently demonstrated good cancer-specific survival in
patients deemed inoperable.1-4 For SBRT, 3-year survival
for stage I lung cancer has been reported to be 56% to
85% with primary tumor local recurrence rates less than
10% at 3 years.2-7 These data have highlighted the benefit
of this therapy in a cohort of patients who previously
went untreated or were inadequately treated with
conventional external beam radiation therapy.
Currently, surgical anatomic resection with mediastinal
lymphadenectomy remains the standard of care for operable
patients with stage I lung cancer.8,9 In the contemporary era
of video-assisted techniques for anatomic resection, 5-year
overall survival (OS) has been reported to be 75% to 80%
with a perioperative mortality rate of 1%.10-12 In small
subsets of potentially operable patients from single-center
studies, SBRT has been associated with good primary tumor
control and OS. Although such findings are encouraging,
these data are not sufficient to supplant surgical resectiondiovascular Surgery c Volume 147, Number 4 1183
Abbreviations and Acronyms
ACE-27 ¼ Adult Comorbidity Evaluation-27
ACOSOG ¼ American College of Surgeons
Oncology Group
BED ¼ biologically effective dose
CT ¼ computed tomography
DFS ¼ disease-free survival
FDG ¼ 2-deoxy-2[18F]fluoro-D-glucose
FEV1 ¼ forced expiratory volume in the first
second of expiration
HIV ¼ human immunodeficiency virus
NSCLC ¼ nonsmall cell lung cancer
OS ¼ overall survival
PET ¼ positron emission tomography
RTOG ¼ Radiation Therapy Oncology Group
SBRT ¼ stereotactic body radiation therapy
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Sas the standard of care in the operable patient and
clinical trials are needed to determine whether outcomes
after SBRT are comparable with anatomic surgical
resection.2,3,13
The ambiguous scenario, however, involves the so-called
high-risk surgical patient with early stage lung cancer.
The American College of Surgeons Oncology Group
(ACOSOG) Z4032 trial has recently examined the role of
sublobar resection with and without brachytherapy in this
subgroup of patients.14 The ACOSOG Z4099/Radiation
Therapy Oncology Group (RTOG) 1021 trial was an
important prospective randomized trial designed to compare
outcomes in high-risk patients with stage I lung cancer
treated with sublobar resection versus SBRT.15 Unfortu-
nately, because of poor accrual, this trial was recently
closed. Our institution has published previous comparative
studies demonstrating comparable cancer-specific survival
after surgery in propensity-matched groups of patients
treated with either SBRT or surgery.16-18 Limitations of
previously published series include small sample size,
inadequate follow-up, inconsistent definitions of recurrence
between the groups, and inadequatematching of the cohorts.
This study was designed to overcome some of the short-
comings of previously published comparisons. This is a retro-
spective propensity-matched comparative study using a large
cohort of patients undergoing SBRT or surgical resection for
stage I lung cancer. This study was designed to compare OS,
disease-free survival (DFS), local recurrence, regional recur-
rence, and distant recurrence using common definitions of
recurrence and survival from recent and ongoingclinical trials.
METHODS
This is a retrospective study of all patients undergoing treatment at
our center with surgery or SBRT for clinical stage I non–small cell lung
cancer (NSCLC) between June 2004 and December 2010. The patients1184 The Journal of Thoracic and Cardiovascular Surwere treated at the Siteman Cancer Center, a National Cancer Institute–
designated comprehensive cancer center at the Washington University
School of Medicine and Barnes-Jewish Hospital in Saint Louis, Missouri.
All patients underwent clinical staging with computed tomography (CT)
and fluorodeoxyglucose (FDG)-positron emission tomography (PET)
imaging. Patients were usually seen initially by a surgeon, and if
considered high-risk for lobectomy were referred for SBRT. In the surgical
patients, the type of surgical resection performed (ie, lobar vs sublobar), the
type of incision, performance of mediastinoscopy, and extent of lymph
node dissection was at the discretion of the treating thoracic surgeon.
NSCLC was ultimately confirmed histologically in all surgical patients.
Patients undergoing SBRT did not undergo routine surgical staging with
either mediastinoscopy or endobronchial ultrasonography.
All pretreatment CT scans and FDG-PET scans were reviewed to
include only those patients with clinical stage I lung cancer. Comorbidity
scores were recorded prospectively using the Adult Comorbidity
Evaluation (ACE-27) scoring system (Appendix E1). The Siteman Cancer
Center Oncology Data Services in the Clinical Outcomes Research Office
at Washington University prospectively assigns comorbidity scores.
Clinic and hospital charts, follow-up CTand FDG-PET scans, as well as
follow-up biopsies were reviewed to determine local tumor recurrence,
regional and distant recurrence, DFS, and OS. Patients were followed
with serial chest radiographs and/or CT scans every 3 to 6 months for
the first 2 years and every 6 to 12 months up to 5 years, then yearly
afterward. FDG-PET imaging was performed if there was suspicion for
recurrence. Local, regional, and distant recurrence definitions were as
defined by the current ACOSOG Z4099/RTOG 1021 trial for comparison
of SBRT and sublobar resection in high-risk patients.19 Briefly, local
recurrence included the primary tumor site, marginal, ipsilateral lobar, or
port site/wound recurrence. An important distinction in this trial is the
definition of local recurrence, which includes both primary tumor failure
and (for sublobar resection or SBRT) failure in the involved lobe.
In some instances, the diagnosis of the first recurrence occurred
simultaneously at different locations accounting for the multiple
recurrences noted in some patients. Exclusion criteria included patients
with small cell lung cancer or extrathoracic cancers that metastasized to
the lung, patients undergoing resection for benign disease, patients without
preoperative staging chest CT and FDG-PET scans, patients with tumors
stages or T3 or higher and patients with clinical N1 or N2 disease noted
on preoperative imaging. For the SBRT patients, every effort was made
to obtain a tissue diagnosis before treatment. A small fraction (14%) of
patients underwent treatment without a tissue diagnosis. These patients
were reviewed at our multidisciplinary conference and in all such patients,
a radiologist reviewed the images and either attempted a biopsy or deemed
a biopsy to be too high risk. These patients were included to demonstrate
the practical management of clinical stage I lung cancer in high-risk or
inoperable patients and to provide a reference for the proportion of patients
treated without a tissue diagnosis relative to other published cohorts.
Details of SBRT planning and delivery at our institution have been
described previously.1 The Varian Trilogy System was used for all SBRT
patients. Target coverage, conformality, and normal tissue constraints were
followed according to the protocol for the RTOG 0236 clinical trial.7
Prescriptions were typically specified at the 60% to 90% (median, 84%)
isodose line so that at least 95% of the prescribed dose covered the planning
target volume. Most SBRT patients received a biologically effective dose
(BED)of at least 100Gy10 (mediandose, 54Gy in3 fractions).BEDwascalcu-
lated usingBEDa/b¼ nd (1þ d/a/b),wheren is the numberof fractions,d is the
dose per fraction, and a/b¼ 10 for tumor in line with previous reports.5,20
BED10 for the SBRT regimens used in this study was 85.5 Gy10 (45 Gy
in 5 fractions, n¼ 6), 86.4 Gy10 (48 Gy in 6 fractions, n¼ 1), 100 Gy10 (50
Gy in 5 fractions, n ¼ 21), 105.6 Gy10 (48 Gy in 4 fractions, n ¼ 1), 112.5
Gy10 (45 Gy in 3 fractions, n¼ 6), 115.5 Gy10 (55 Gy in 5 fractions, n¼ 3),
132Gy10 (60Gy in 5 fractions, n¼ 4), and 151.2 Gy10 (54Gy in 3 fractions,
n ¼ 110).gery c April 2014
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SSAS version 9.3 (SAS Institute, Inc, Cary, NC) was used to perform all
statistical analyses. Descriptive statistics included the mean standard de-
viation of continuous variables and counts and proportions of categorical
data by group. Continuous and categorical variables were compared by a
Kruskal-Wallis test and the chi-squared test, respectively. OS is defined
from the date of treatment to the date of death or the last follow-up. DFS
was defined as being alive without disease. The patients with disease or
those who died are counted as disease. DFS was defined as the time from
date of treatment to date of cancer recurrence, death, or last follow-up.
Local, regional, or distant recurrence is defined as having local, regional,
or distant failure, censored at any other recurrence or at last follow-up.
Freedom from local, regional, or distant recurrence is defined as the time
from date of treatment to date of recurrence or last follow-up. Kaplan-
Meier curves provided unadjusted survival estimates for patients across
strata. Differences between strata were determined by log-rank tests. Based
on previously published comparisons, an initial propensity-matched
analysis was performed to compare patients in the SBRT and surgery
groups based on age, tumor stage, and ACE comorbidity score. To provide
additional variables, a subsequent propensity score was estimated using
age, forced expiratory volume in the first second of expiration (FEV1,
%), tumor size, tumor location, and ACE comorbidity score. The matched
pair was found using a caliper technique with a standard deviation defined
as 0.075 of the estimated propensity score for both groups. All statistical
tests were 2-sided using an a ¼ 0.05 level of significance.
The study and awaiver of informed consent were approved by theWash-
ington University School of Medicine Human Research Protection Office.RESULTS
Four hundred fifty-eight patients underwent primary sur-
gical resection for clinical stage I NSCLC and 151were
treated with SBRT (Figure 1). Table 1 outlines the demo-
graphics and preoperative comorbidity comparisonsFIGURE 1. CONSORT diagram outlining selection of patients treated w
NSCLC, Non–small cell lung cancer; SBRT, stereotactic body radiation th
expiratory volume in the first second of expiration.
The Journal of Thoracic and Carbetween the unmatched cohorts of surgery and SBRT
patients. Surgery patients were younger and had lower
comorbidity scores. Median follow-up for the surgery
cohort was 2.83 years and the median follow-up for the
SBRT cohort was 1.95 years. There were 165 (36%)
clinical T2 lesions in the surgery group versus 41 (27%)
in the SBRT group (P ¼ .0456). Pathologic N1 and N2
disease were identified in 11.8% (n ¼ 54) and 3.0%
(n ¼ 14) of surgery patients. In addition, 3.1% (n ¼ 14)
of surgical patients were found to be pathologic T3 and
2.2% (n ¼ 10) were pathologic T4. Of 293 clinical T1
lesions, 18.4% (54) were found to be pathologic T2. No
patients in the SBRT cohort received adjuvant therapy but
17.5% (80) were confirmed to have received adjuvant
therapy in the surgical cohort. Among surgical resections,
75.6% (n ¼ 347) underwent lobectomy, 5.9% (n ¼ 27)
underwent pneumonectomy/bilobectomy, and 18.3%
(n ¼ 84) underwent sublobar resection. Thirty-day mortal-
ity was 1.09% (5/458) for the surgery group and 0.66% (1/
151) for the SBRT group (not significant). The cause of
death in the patient who died within 30 days of SBRT
treatment was unknown and was defined as a sudden death.
Three-year OS for surgery was 78% and DFS was 72%
(Figure E1 and Appendix E2). Three-year OS for SBRTwas
47% and DFS was 42%. Table 2 outlines the total propor-
tion of local, regional, and distant recurrences for both
cohorts. The overall local recurrence rate for surgery was
2.6%. The local recurrence rate for SBRT was 10.7%.ith either SBRT or surgery for stage I non–small cell lung cancer.
erapy; Ca, cancer; ACE, Adult Comorbidity Evaluation; FEV1, forced
diovascular Surgery c Volume 147, Number 4 1185
FIGURE 2. Overall survival (A); disease-free survival (B); and freedom from local (C), regional (D), and distant (E) recurrence between thematched cohorts of
surgical and SBRT patientsmatched for age, tumor size, tumor location, FEV1%, andACE comorbidity score. Final propensitymatching resulted in 56 patients
in each cohort. SBRT, Stereotactic body radiation therapy;FEV1, forced expiratory volume in the first second of expiration;ACE, Adult Comorbidity Evaluation.
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SSurgical techniques were consistent throughout the study
period. However, the dose of radiation administered for
SBRT did change over time after identifying that doses
less than 100 Gy10 were associated with higher local
recurrence rates and worse OS in clinical studies.20,21 In
this analysis, only 7 of 151 patients received less than 100
Gy10, with no statistically significant difference in OS or
local recurrence based on the dose.
Within the SBRT cohort, 14% of patients were treated
without conclusive biopsy proof of cancer when an
attempt at tissue diagnosis was unsuccessful, or when a
needle biopsy was not pursued based on the perceived
high risk of pneumothorax. There was no difference in
OS or freedom from local recurrence among SBRT
patients with or without a tissue diagnosis before
treatment (Figure E2).
Most patients within the surgical cohort were treated
with lobectomy (347 of 458, 75.8%). Pneumonectomy
or bilobectomy was performed in 5.9% (27), and
18.3% (84) were treated with sublobar resection. Among
the sublobar resections, 41.7% (35) were anatomic1186 The Journal of Thoracic and Cardiovascular Surresections (segmentectomy) and 58.3% (49) were non-
anatomic wedge resections. Tumor margin distance was
not recorded in these patients. There was no difference
in OS between the different types of resections per-
formed. In the unmatched comparison, local recurrence
rates after lobectomy, sublobar resection, and SBRT
were 1.73% (n ¼ 6), 7.14% (n ¼ 6), and 10.67%
(n ¼ 16), respectively (P< .0001 lobectomy vs SBRT,
P ¼ .02 lobectomy vs sublobar resection, P ¼ .5 sublobar
resection vs SBRT).
Among the 458 patients with clinical stage I lung cancer,
14.8% (68/458) were upstaged at surgery and found to have
occult N1 or N2 disease. For patients with occult
nodal disease, 3-year and 5-year OS were 66% and 43%,
respectively. For patients without occult nodal disease,
3- and 5-year OS were 80% and 68%, respectively.
In an attempt to account for disparate cohorts, propensity
matching was performed to identify 2 similar groups of pa-
tients within the SBRT and surgery cohorts for comparison.
Age, ACE-27 score, and T status were used for propensity
score estimation based on previous publications by us andgery c April 2014
TABLE 1. Patient and disease characteristics for unmatched patients
Variable SBRT (n ¼ 151) Surgery (n ¼ 458) P value*
Mean age, y  SD 74.4  9.4 65.8  10.5 <.0001
Age>75 y, n (%) 73 (48.3) 89 (19.4) <.0001
Male, n (%) 80 (53.0) 212 (46.3) .1535
Race, n (%)y
White 132 (88.0) 403 (88.0)
Black 16 (10.7) 50 (10.9) .9686
Asian 2 (1.3) 5 (1.1)
Weight, kg  SDz 78.9  22.3 78.5  20.9 .7391
T2, n (%) 41 (27.2) 165 (36.0) .0456
Comorbidity score, n (%)y <.0001
0-1 37 (32.7) 268 (64.1)
2-3 76 (67.3) 150 (35.9)
Smoking, n (%)y .2567
Yes 126 (85.1) 406 (88.7)
No 22 (14.9) 52 (11.4)
Hypertension, n (%)z .7003
Yes 90 (63.4) 136 (65.4)
No 52 (36.6) 72 (34.6)
Size of tumor, cm  SD 2.6  1.0 2.9  1.7 .4522
Location of tumor, n (%) <.0001
Peripheral 122 (84.1) 277 (66.4)
Central 23 (15.9) 140 (33.6)
FEV1, L, mean  SDz 1.4  0.7 (n ¼ 95) 2.1  0.8 (n ¼ 449) <.0001
FEV1, L, mean%  SDz 57  25 (n ¼ 94) 79  20 (n ¼ 444) <.0001
DLCO, mL, mean  SDz 10.8  4.9 (n ¼ 59) 16.2  6.2 (n ¼ 387) <.0001
DLCO, mL, mean%  SDz 53  24 (n ¼ 67) 74  25 (n ¼ 382) <.0001
Surgery procedure type, n (%)
Bilobectomy — 10 (2.2)
Lobectomy — 347 (75.8)
Pneumonectomy — 17 (3.7)
Segmentectomy — 35 (7.6)
Wedge — 49 (10.7)
SD, Standard deviation; FEV1, forced expiratory volume in the first second of expiration;DLCO, diffusing capacity of lung for carbon monoxide; SBRT, stereotactic body radiation
therapy. *Chi-squared or Fisher exact test for categorical variables; Kruskal-Wallis test for continuous variables. yThe denominator for the percentages is the sum of patients
across all categories in the SBRT or surgery group, respectively, excluding missing values. zHigh frequency of missing values.
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Sothers.2,17,18 With the propensity-matched model, 83
patients were matched from each of the cohorts. For the
matched comparison, 3-year OS was 75% for surgery
versus 47% for SBRT (P < .0004) (Figure E3 and
Appendix E3). Three-year DFS for surgery was 67% versus
42% for SBRT (P<.0002). Three-year freedom from local
recurrence for the surgical cohort was 97% versus 90% for
the SBRT cohort (P < .01). Three-year freedom from
regional recurrence and from distant recurrence did not
differ between the matched cohorts.
Recognizing the limitations of these previously used
matching criteria, we attempted to include additionalTABLE 2. Total proportion of local, regional, and distant recurrences occu
No recurrence (%) Local recurrence (%)
Surgery 77.7 2.6
SBRT 66 10.7
SBRT, Stereotactic body radiation therapy.
The Journal of Thoracic and Carfactors that may influence patient selection for each
treatment. We therefore performed an additional propen-
sity-matched comparison that used age, tumor size, tumor
location (central vs peripheral), FEV1%, and ACE
comorbidity score. This resulted in 56 matched patients in
each cohort. Table 3 outlines characteristics of each
matched cohort. Figure 2 outlines overall survival,
disease-free survival, and local recurrence-free survival
among these matched groups (confidence intervals
provided in Appendix E4). In the final matched comparison,
3-year overall survival was 52% versus 68% for SBRT
and surgery, respectively (P ¼ .05), whereas disease-freerring in all patients with stage 1 NSCLC treated with surgery or SBRT
Regional recurrence (%) Distant recurrence (%)
7.0 12.7
10 13.3
diovascular Surgery c Volume 147, Number 4 1187
TABLE 3. Patient and disease characteristics for matched patients*
Variable SBRT (n ¼ 56) Surgery (n ¼ 56) P valuey
Age, mean y  SD 70.7  10.6 70.0  8.1 .6496
Age>75 y, n (%) 20 (35.7) 16 (28.6) .4183
Male, n (%) 29 (51.8) 32 (57.1) .5692
Race, n (%)z .3207
White 49 (89.1) 53 (94.6)
Black 6 (10.9) 3 (5.4)
Weight (lb)x 175.6  54.5 164.3  44.1 .3355
T2, n (%) 16 (28.6) 24 (42.9) .1147
Comorbidity score, n (%) .5702
2-3 31 (55.4) 28 (50.0)
Smoking, n (%)z .2060
Yes 51 (92.7) 55 (98.2)
No 4 (7.3) 1 (1.8)
Hypertension, n (%)z .6989
Yes 33 (62.3) 6 (75.0)
No 20 (37.7) 2 (25.0)
Size of tumor, mm  SD 2.5  1.1 3.0  1.6 .3095
Location of tumor, n (%) .3408
Peripheral 49 (87.5) 52 (92.9)
Central 7 (12.5) 4 (7.1)
FEV1, mean  SDz 1.6  0.7 1.6  0.6 .6156
FEV1, mean%  SD 64  24 62  18 .8522
DLCO, mean  SDx 11.6  5.3 14.3  4.8 .0020
DLCO, mean%  SDx 55  20 73  27 .0001
Surgery procedure type, n (%)
Bilobectomy — 1 (1.8)
Lobectomy — 44 (78.6)
Pneumonectomy — 0
Segmentectomy — 6 (10.7)
Wedge — 5 (8.9)
SBRT, Stereotactic body radiation therapy; SD, standard deviation; FEV1, forced expiratory volume in the first second of expiration; DLCO, diffusing capacity of lung for carbon
monoxide. *Age, comorbidity score, FEV1 (%), tumor location, and tumor size were used for propensity score estimation. c-statistics is 0.824. The matched pair is found using a
caliper technique with a standard deviation defined as 0.075 of the estimated propensity score for both groups. yChi-squared or Fisher exact test for categorical variables;
Kruskal-Wallis test for continuous variables. zThe denominator for the percentages is the sum of patients across all categories in the SBRT or surgery group, excluding missing
values. xMissing values.
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Ssurvival was 47% versus 65% (P ¼ .01). Two-, 3-, 4-, and
5-year local recurrence-free survival for SBRT was 91%,
91%, 81%, and 40%, respectively, versus 98%, 92%,
92%, and 92% for surgery (P ¼ .07). Regional and distant
recurrence-free survival were again similar among the
groups.
DISCUSSION
The development and more widespread use of ablative
nonoperative treatment modalities for stage I NSCLC
such as SBRT and radiofrequency ablation have prompted
us to further evaluate the role of these therapies relative to
surgical resection. Comparative studies of these modalities
have been limited in number and are often difficult to
interpret because of variability in methodological issues.
Although this current study is retrospective, we have
attempted to rigorously compare SBRT and surgical
resection in stage I NSCLC outcomes using strictly defined
local and regional recurrence criteria accepted by National1188 The Journal of Thoracic and Cardiovascular SurCancer Institute cooperative groups.19 These data highlight
the challenges and limitations of attempting to match
disparate groups of patients retrospectively for a
comparative survival analysis. The final matched analysis
included one third of the original SBRT cohort and one
ninth of the surgery cohort. This final matched comparison
suggests improved OS and DFS with surgery versus SBRT
with a trend toward improved local recurrence-free
survival, albeit not statistically significant in this small
cohort. Despite our efforts to match patients retrospectively,
it remains difficult to objectively define which subset of
high-risk patients would benefit from one modality versus
the other.
As expected, OS is better in unmatched surgical patients
compared with patients treated with SBRT generally
because of a higher burden of comorbidities in the
SBRT cohort. Likewise, despite our efforts at matching
patients, other unmeasured covariates may be taken into
consideration when deeming a patient fit for surgery. Onegery c April 2014
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Svariable included in the final matched comparison was
pretreatment FEV1, which was documented in only 62%
of patients treated with SBRT versus 97% of surgical
patients. Therefore, this excludes several patients in the
SBRT group who were available for comparison (ie,
n ¼ 56) compared with our initial matched comparison
that included age, tumor stage, and comorbidity score (ie,
n ¼ 83). Although FEV1 is frequently used to risk stratify
surgical patients, the exclusion of this variable in a
significant number of patients treated with SBRT highlights
that other potentially unmeasured covariates may weigh in
the decision to pursue nonoperative treatment at our
institution.
In previously published studies, cancer-specific survival
has been similar in matched cohorts of patients.6,18,22,23
Given that the ACOSOG/RTOG randomized trial used OS
and DFS end points, we elected to use these end points.
We recognize that they may be considered biased for
surgical treatment as noncancer-related mortality may
occur more frequently in very high-risk patients undergoing
SBRT. Alternatively, cause-specific survival is a favored
end point for treatment modalities when patients have a
high likelihood of mortality from associated comorbidities.
Although survival outcomes seem intuitive, the consistent
use of similar outcome measures for patients treated
surgically and with SBRT will be important in future
comparative studies.
Given the median follow-up of 2.8 years and a
predominance of lobar resections, the local recurrence
rate of 2.6% is similar to other reported series of compara-
ble surgical resections.10,24 A previous publication from our
institution excluding sublobar resections demonstrated
similar postoperative recurrence patterns.23 True local
recurrence after lobectomy would likely be limited to a
stump recurrence. Higher local recurrence rates have been
reported within the surgical literature, sometimes attributed
to inclusion of all locoregional recurrences within the local
recurrence definition.25 Surgical cohorts with a larger
proportion of nonanatomic sublobar resections may also
result in a higher reported local recurrence rate as staple
line recurrence would occur with greater frequency.
Inclusion of more central lesions requiring pneumonec-
tomy/bilobectomy may result in a higher reported local
recurrence rate although this represented a small proportion
of resections in this study.
The overall local recurrence rate after SBRTwas 10.7%
in this series. Within the SBRT literature, various
definitions of recurrence have been used to report outcomes
from focal ablative therapy. Recurrence outcomes may
include primary tumor site recurrence, marginal recurrence,
or intralobar recurrence.3,7,23,26 Recognizing the variability
in the definitions of recurrence in both the SBRT and
surgical literature, one of the strengths of this report is
that similar criteria were used to define local recurrenceThe Journal of Thoracic and Carbetween the 2 cohorts. A potential criticism of this
analysis is that we chose to limit our evaluation of
recurrence to first recurrence, a commonly reported end
point in the surgical literature.
Anatomic resection, particularly lobectomy, has been
associated with excellent long-term survival ranging from
65% to 80% for stage I NSCLC.9-11,27 Furthermore,
contemporary series of minimally invasive lobectomy
have been associated with minimal perioperative
mortality and 5-year OS ranging from 75% to
90%.10,11,28 Ongoing surgical trials are attempting to
identify the role of sublobar resection in stage I lung
cancer, but the predominance of lobectomy in this series
highlights our institutional bias toward lobar resection,
reserving sublobar resection for high-risk patients with
poor pulmonary reserve. An ongoing challengewith clinical
trials, as well as within clinical practice, is that current
guidelines defining the high-risk patient are subjective
and prone to physician bias. A recent secondary analysis
of clinical trial inclusion criteria for SBRT underscored
this bias by demonstrating that many patients who were
considered inoperable were perhaps reasonable surgical
candidates.29 In the absence of a clinical trial or a
prospective database, there is currently no objective
algorithm to guide the assignment of surgery versus SBRT.
Attempts to objectively stratify risk within the surgical
population have been challenging. Other published work
at our institution has suggested that the Charlson Comorbi-
dity Score may serve as a better measure of comorbidity
than the ACE score in these populations.30 Other risk
models based on the European Thoracic Database and the
Society of Thoracic Surgeons Database have attempted to
model perioperative morbidity, length of stay, and
assessment of quality of care in thoracic surgery across all
surgical patients. These models are not yet robust enough
to guide decision making regarding treatment assignment
or classification of the very high-risk surgical patient for
whom alternative therapies may be preferable.31-33 In
conjunction with this, alternative outcome measures such
as toxicity, quality of life, and functional capacity after
treatment are important components of comparative
studies. As comorbidity increases and life expectancy
decreases, it is reasonable to presume that patient-
reported outcomes such as health-related quality of life
will take on higher importance compared with absolute
OS. We must be cognizant that patients may be willing to
sacrifice some long-term survival benefit related to surgery
for a potential preservation of quality of life that may be
presumed to be associated with SBRT treatment. Any
attempt to construct an algorithm to guide treatment
decisions in these patients must pay attention to patient
preferences and the factors that guide such preferences.
In this study, 14.8% of clinical stage I patients were
ultimately found to have nodal disease at resection with adiovascular Surgery c Volume 147, Number 4 1189
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niques, some patients with involved nodes are likely missed
in the SBRT group. Our reported incidence of occult nodal
disease after resection in these clinical stage I patients is
similar to that observed in other reports.10,16 Overall,
19.4% of clinical stage I patients treated with surgery
were eventually shown to be pathologic stage II, III, or
IV. Furthermore, patients with a higher T stage than
clinically predicted may also affect local recurrence rates
among patients treated with SBRT. Future improvements
in clinical staging with identification of occult nodal or
metastatic disease may allow for earlier use of adjuvant
treatment in patients treated with SBRT.
This study presents a concerted effort to use trial-based
guidelines to compare outcomes between different
treatment modalities in patients with stage I lung cancer.
This work highlights some of the current limitations of
retrospective comparative studies in disparate populations.
The apparent advantages of surgery in terms of OS and
DFS, and potentially local recurrence, will still need to
be confirmed in a prospective randomized fashion. A
reasonable goal for work like this would be to improve
our ability to draw on objective data to guide the allocation
of appropriate treatment in patients with stage I lung cancer
at increased risk for perioperative death and surgical
complications.
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SDiscussion
Dr James D. Luketich (Pittsburgh, Pa). Dr Crabtree, I would
like to congratulate you and your colleagues for a very timely
look at the significant increase we are seeing in referral patients
for stereotactic radiation therapy for stage I non–small cell lung
cancer. My first question relates to the absolute proportion of stage
I patients during this time frame that were referred to stereotactic
radiosurgery of approximately 25%. Given the study is now 3 to 4
years old, are you seeing an increase in that number of 25% that are
actually getting stereotactic radiosurgery, and along those lines, is
the technology changing? CyberKnife, Trilogy, TrueBeam, is
there a single device they are using? Have you seen any advantages
or any comments of one technology over the other?
Regarding the absolute results, you pointed out several things in
the comparison between these groups, and the total comparison
and propensity match showed a significant advantage in the
surgical group at 3 and 5 years in terms of disease-free survival.
Yet in the more detailed analysis, there is a lack of a clinically
significant difference in the regional recurrence, survival or
distant, and in the propensity-matched groups only a modest
improvement in local recurrence. So it seems that SBRT is
working fairly good locally. So if patients are not having local or
regional recurrence at a higher rate, ultimately can you comment
more on the cancer-specific survival? I see that difference in
disease-free survival, and how are you determining at the time of
death in this retrospective review that it was indeed cancer-related
or were you able to do that?
Dr Crabtree. Thank you, Dr Luketich. Great points. The first
point, I don’t have the specific numbers or the percentages of
patients that we have sent to stereotactic radiotherapy over the
time of the study. I would say, generally speaking, over that time
our number of evaluations of clinical stage I lung cancers has
gone up, and perhaps the percentage of stereotactic patients has
gone up slightly as a result of us making an assessment that it
may be adequate in those patients.
I think what we have seen as we have delved into this newer
technology of stereotactic therapy is we have had patients come
out of the woodwork who probably historically would never have
been treated at all or never been evaluated for treatment. Now that
referring physicians are aware of this technology, I think we are
seeing more of those, and that probably accounts for most of the
higher percentage of stereotactic patients that we have seen in this
study.
The second question I think is a very important point, and I
highlighted it in the first point of the conclusions. It is very difficultThe Journal of Thoracic and Carfor us to match these patients, because they’re very disparate
populations. Most of the survival difference that we see in terms
of disease-free survival and overall survival is likely attributed to
some other comorbidities. I will say, however, that the radiation
oncologists make the argument that, because in this population
we see no difference in regional failure or distant failure, that is
an advantage or an argument for stereotactic radiotherapy. We
are still seeing a difference in local recurrence, which I think is
extremely important, and compared with lobectomy, there is about
a 5-fold increase in local recurrence in the stereotactic group.
One more comment on that. The theory that the radiation
oncologists have is that there is some kind of immune effect,
that treating a tumor focally with stereotactic therapy somehow
affects the nodal disease. My potential common sense theory is
that at 3 years, 53% of the stereotactic patients are dead and at 5
years 75% are dead, and we clearly are not very good at defining
recurrences radiographically in the nonliving patient.
Dr Scott Swanson (Boston, Mass). I really enjoyed your talk,
Traves. Along those same lines, I have a couple of questions.
One, 15% nodal disease was seen in your surgical cohort, so
presumably that is true on the radiation side, but yet you couldn’t
demonstrate a local regional failure. So what is your impression or
hypothesis about what happens to those patients?
And number 2, it seems important to really understandmorbidity.
Doyou have any data onmorbidity for the radiation patients? It can’t
be zero, so it is always a little later that you see these radiation side
effects. Are you following these patients and getting a sense for
pneumonias, pulmonary fibrosis, issues around respiration, because
I think with minimally invasive techniques, our morbidity is pretty
limited, and I don’t really understand what it is for SBRT.
Dr Crabtree. Thank you, Dr Swanson. Again, great points.
Again, although there is certainly a higher local recurrence rate
for stereotactic therapy compared with surgery, in terms of
regional and distant recurrences, when we are treating these very
sick patients with multiple comorbidities with stereotactic therapy,
I think that their mortality prevents us from being able to identify
regional and distant recurrences, and I think trying to extrapolate
that data and say that there is some equivalence in a low-risk
population is inappropriate. But we would only be able to answer
that question as more low-risk patients who are surviving are
treated with stereotactic therapy.
The second question is a very important point, because we
certainly take a lot of heat in terms of 30- and 90-day morbidity
in the resected patients. In contrast, most of the stereotactic
complications occur 6 months to even a year out, including
radiation pneumonitis, rib fractures, and pain, and it’s actually
very hard to track those complications in the stereotactic patients.
For purposes of this study, however, I do not have accurate data
on the morbidity of stereotactic therapy.
Dr Nasser Altorki (New York, NY). One of the hardest things is
to document local recurrence after SBRT. Many times I find that if
you operate on these patients for failure, you will find that they
have a small number of interspersed cancer cells within a dense
desmoplastic stroma. How was that done in your study and do
you have any insights into how we do it, documentation of local
recurrence in the SBRT arm?
Dr Crabtree. In this population it was almost all radiographic,
and, as you know, in the stereotactic patients, there is controversydiovascular Surgery c Volume 147, Number 4 1191
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represents a recurrence. This was actually very challenging to
work through with our radiation oncologists, but I reviewed every
one of the cases with the radiation oncologist and determined
radiographically if it was a recurrence.
It should be, in a low-risk population, that we get tissue
confirmation. In this population, that just wasn’t practical.
Dr Arjun Pennathur (Pittsburgh, Pa). With the concern of
limiting toxicity of stereotactic radiosurgery in central lesions
and adjustment of dose taking into account the location of the
tumor, could you tell us howmany of them were peripheral lesions
and how many of them were central lesions, because that in itself
has an implication in terms of toxicity as well as the outcome for
the patients.
The second thing is the issue of tissue diagnosis. Fifteen percent
of the SBRT patients did not have a tissue diagnosis, and in your
propensity matching, you matched for T stage and other factors,
but could you have considered eliminating the patients who did
not have a tissue diagnosis at all from the propensity matching
to get that out of the equation, because some of these patients in
whom you did not have a tissue diagnosis could have had benign
disease or they could have had something like carcinoid or small
cell cancer or something else.
Dr Crabtree. Excellent point. The first question about
whether they were central or peripheral, most of these lesions
were peripheral lesions, partly because obviously the radiation
oncologists know there is more toxicity with the central
lesions, and so most central lesions are currently being done on
study.
For the second question, I think that is very important for us to
also understand in the literature. In our SBRT group for this study,
14% didn’t have a tissue diagnosis. I did include them because it is
kind of the practical nature of the practice. We did a subgroup1192 The Journal of Thoracic and Cardiovascular Suranalysis comparing survival and recurrence of the patients who
had a tissue diagnosis and those who didn’t, and there was no
difference. That is a somewhat crude way to deal with this issue.
That number of 14% is actually much lower than what it was in
our original publication a few years ago.
I would highlight that the Dutch group, who publishes quite a
bit on stereotactic radiotherapy, purports an algorithm based on
PET that can completely clinically predict whether or not someone
has a cancer, and in their most recent publication, only one-third of
the patients actually had a tissue diagnosis, and I think that would
be unacceptable, in a low-risk operable population. There is
nothing better to improve your cancer-specific survival than
treating granulomas with stereotactic therapy.
Dr David C. Rice (Houston, Tex). Traves, a great paper. I really
hate to advocate on behalf of the radiation oncologists here, but, as
you point out, the comorbidity score probably doesn’t take into
account resectability, and, therefore, did you go back and look at
the patients who were treated with radiation to see what their
pulmonary function was, how many of those could not possibly
have a lobectomy anyhow? It seems to me that the comparison
is a little slanted in favor of the lobectomy group here.
Dr Crabtree. That is another great question. Certainly the ACE
comorbidity score that we used was a somewhat crude measure.
The problem is identifying this high-risk population or even
the inoperable population. Even within our Society, we don’t
truly know who these high-risk patients are. Efforts with the
Thoracoscore and the STS database by Dr Boffa and Dr Wright
and Ben Kozower, and even Dr Ferguson yesterday, really shows
that these risk models are not yet robust enough to allow us to truly
identify these high-risk patients.
We did look at pulmonary function in the surgical group, but
because of other comorbidities as well, the data on pulmonary
function were incomplete in the stereotactic group.gery c April 2014
APPENDIX E1. ADULT COMORBIDITY
EVALUATION-27
Identify the important medical comorbidities and grade
severity using the index. Overall comorbidity score is
defined according to the highest ranked single ailment,
except when 2 or more grade 2 ailments occur in different
organ systems. In this situation, the overall comorbidity
score should be designated as grade 3.
Cogent comorbid ailment Grade 3: severe decompensation Grade 2:moderate decompensation Grade 1: mild decompensation
Cardiovascular system
Myocardial infarct 6 mo ago >6 mo ago By ECG only, age undetermined
Angina/coronary artery disease Unstable angina Chronic exertional angina
Recent ( 6 mo) CABG or PTCA
Recent ( 6 mo) coronary stent
ECG or stress test evidence or
catheterization evidence of
coronary disease without
symptoms
Angina pectoris not requiring
hospitalization
CABG or PTCA (>6 mo)
Coronary stent (>6 mo)
CHF Hospitalized for CHF within past
6 mo
Ejection fraction<20%
Hospitalized for CHF>6 mo before
CHF with dyspnea that limits
activities
CHF with dyspnea that has responded
to treatment
Exertional dyspnea
Paroxysmal nocturnal dyspnea
Arrhythmias Ventricular arrhythmia 6 mo Ventricular arrhythmia>6 mo
Chronic atrial fibrillation or flutter
Pacemaker
Sick sinus syndrome
Supraventricular tachycardia
Hypertension DBP 13 mm Hg
Severe malignant papilledema or
other eye changes
Encephalopathy
DBP ¼ 115-129 mm Hg
DBP ¼ 90-114 mm Hg while taking
antihypertensive medications
Secondary cardiovascular symptoms:
vertigo, epistaxis, headaches
DBP ¼ 90-114 mm Hg while not
taking antihypertensive
medications
DBP<9 mm Hg while taking
antihypertensive medications
Hypertension, not otherwise specified
Venous disease Recent PE (6 mo)
Use of venous filter for PE
DVT controlled with coumadin or
heparin
Old PE>6 mo
Old DVT no longer treated with
coumadin or heparin
Peripheral arterial disease Bypass or amputation for gangrene or
arterial insufficiency<6 mo ago
Untreated thoracic or abdominal
aneurysm (6 cm)
Bypass or amputation for gangrene or
arterial insufficiency>6 mo ago
Chronic insufficiency
Intermittent claudication
Untreated thoracic or abdominal
aneurysm (<6 cm)
Status post abdominal or thoracic
aortic aneurysm repair
Respiratory system
Marked pulmonary insufficiency
Restrictive lung disease or COPD
with dyspnea at rest despite
treatment
Chronic supplemental O2
CO2 retention (PCO2>5mm Hg)
Baseline PO2<50 mm Hg
FEV1 (<50%)
Restrictive lung disease or COPD
(chronic bronchitis, emphysema, or
asthma) with dyspnea that limits
activities
FEV1 (51%-65%)
Restrictive lung disease or COPD
(chronic bronchitis, emphysema, or
asthma) with dyspnea that has
responded to treatment
FEV1 (66%-80%)
Gastrointestinal system
Hepatic Portal hypertension and/or
esophageal bleeding 6 mo
(encephalopathy, ascites, jaundice
with total bilirubin>2 mg/dL)
Chronic hepatitis, cirrhosis, portal
hypertension with moderate
symptoms, compensated hepatic
failure
Chronic hepatitis or cirrhosis without
portal hypertension
Acute hepatitis without cirrhosis
Chronic liver disease manifested on
biopsy or persistently increased
bilirubin level (>3 mg/dL)
(Continued)
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Continued
Cogent comorbid ailment Grade 3: severe decompensation Grade 2:moderate decompensation Grade 1: mild decompensation
Stomach/intestine Recent ulcers ( 6 mo ago) requiring
blood transfusion
Ulcers requiring surgery or
transfusion>6 mo ago
Diagnosis of ulcers treated with
medication
Chronic malabsorption syndrome
Inflammatory bowel disease on
medications or history with
complications and/or surgery
Pancreas Acute or chronic pancreatitis with
major complications (phlegmon,
abscess, or pseudocyst)
Uncomplicated acute pancreatitis
Chronic pancreatitis with minor
complications (malabsorption,
impaired glucose tolerance, or
gastrointestinal bleeding)
Chronic pancreatitis without
complications
Renal system
End-stage renal disease Creatinine level>3 mg/dL with
multiorgan failure, shock, or sepsis
Acute dialysis
Chronic renal insufficiency with
creatinine level>3 mg/dL
Chronic dialysis
Chronic renal insufficiency with
creatinine level of 2-3 mg/dL
Endocrine system (code the comorbid ailments with an asterisk in both the endocrine system and other organ systems if applicable)
Diabetes mellitus Hospitalization 6 mo for diabetic
ketoacidosis
Diabetes causing end-organ failure
- retinopathy
- neuropathy
- nephropathy
- coronary disease
- peripheral arterial disease
Type 1 diabetes without
complications
Poorly controlled type 2 diabetes with
oral agents
Type 2 diabetes controlled by oral
agents only
Neurologic system
Stroke Acute stroke with significant
neurologic deficit
Old stroke with neurologic residual Stroke with no residual
Past or recent transient ischemic
attack
Dementia Severe dementia requiring full
support for activities of daily living
Moderate dementia (not completely
self-sufficient, needs supervising)
Mild dementia (can take care of self)
Paralysis Paraplegia or hemiplegia requiring
full support for activities of daily
living
Paraplegia or hemiplegia requiring
wheelchair, able to do some self
care
Paraplegia or hemiplegia, ambulatory
and providing most of self care
Neuromuscular MS, Parkinson disease, myasthenia
gravis, or other chronic
neuromuscular disorder and
requiring full support for activities
of daily living
MS, Parkinson disease, myasthenia
gravis, or other chronic
neuromuscular disorder, but able to
do some self care
MS, Parkinson disease, myasthenia
gravis, or other chronic
neuromuscular disorder, but
ambulatory and providing most of
self care
Psychiatric
Recent suicidal attempt
Active schizophrenia
Depression or bipolar disorder
uncontrolled
Schizophrenia controlled with
medication
Depression or bipolar disorder
controlled with medication
Rheumatologic (including rheumatoid arthritis, systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis)
Connective tissue disorder with
secondary end-organ failure (renal,
cardiac, central nervous system)
Connective tissue disorder on steroids
or immunosuppressant
medications
Connective tissue disorder on
nonsteroidal antiinflammatory
drugs or no treatment
Immunologic system (AIDS should not be considered a comorbidity for Kaposi sarcoma or non-Hodgkin lymphoma)
AIDS Fulminant AIDS with Karposi
sarcoma, Mycobacterium avium
intracellulare, Pneumocystis
carinii pneumonia (AIDS-defining
illness)
HIV+ with history of defining illness
CD4+<200/mL
Asymptomatic HIV+ patient
HIV+ without history of AIDS-
defining illness
CD4+>200/mL
(Continued)
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Cogent comorbid ailment Grade 3: severe decompensation Grade 2:moderate decompensation Grade 1: mild decompensation
Malignancy (excluding cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, carcinoma in situ, and intraepithelial neoplasm)
Solid tumor including melanoma Uncontrolled cancer
Newly diagnosed but not yet treated
Metastatic solid tumor
Any controlled solid tumor without
documented metastases, but
initially diagnosed and treated
within the last 5 y
Any controlled solid tumor without
documented metastases, but
initially diagnosed and treated>5 y
ago
Leukemia and myeloma Relapse
Disease out of control
First remission or new diagnosis<1 y
Chronic suppressive therapy
History of leukemia or myeloma with
last treatment>1 y prior
Lymphoma Relapse First remission or new diagnosis<1 y
Chronic suppressive therapy
History of lymphoma with last
treatment>1 y prior
Substance abuse (must be accompanied by social, behavioral, or medical complications)
Alcohol Delirium tremens Active alcohol abuse with social,
behavioral, or medical
complications
History of alcohol abuse but not
presently drinking
Illicit drugs Acute withdrawal syndrome Active substance abuse with social,
behavioral, or medical
complications
History of substance abuse but not
presently using
Body weight
Obesity Morbid (ie, body mass index
38 kg/m2)
Overall comorbidity score (circle 1) 0 1 2 3 9
None Mild Moderate Severe Unknown
ECG, Electrocardiogram;CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty;CHF, chronic heart failure;DBP, diastolic blood pressure;
PE, pulmonary embolism; DVT, deep vein thrombosis; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second of expiration;
MS, multiple sclerosis; HIV, human immunodeficiency virus.
APPENDIX E2
(1) Overall, (2) disease-free, (3) local-, (4) regional-, and (5)
distant recurrence-free survival are presented for the entire
cohort of surgical (n ¼ 458) and stereotactic body radiation
therapy (SBRT, n ¼ 151) patients with clinical stage I
non–small cell lung cancer (including confidence intervals
for survival analysis).
1A. From date of treatment to follow-up or death (years). Median
follow-up is 2.42 years
Group n Mean Minimum Maximum Median
All 609 2.79 0.01 7.44 2.42
Surgery 458 3.00 0.01 7.44 2.83
SBRT 151 2.15 0.05 6.32 1.95
SBRT, Stereotactic body radiation therapy.
1B. Summary of the number of deaths and the number of patients alive
at last follow-up (overall survival is defined from date of treatment to
date of death or the last follow-up)
Group
Total
no. of
patients
Total
no. of
deaths
Total
no. alive
at last
follow-up
Percent alive
at last follow-up
SBRT 151 81 70 46.36
Surgery 458 121 337 73.58
609 202 407 66.83
SBRT, Stereotactic body radiation therapy.
1C. Overall survival
Group Year Percent alive 95% Confidence interval
SBRT 1 0.82 (0.75, 0.87)
SBRT 3 0.47 (0.37, 0.55)
SBRT 5 0.25 (0.14, 0.37)
Surgery 1 0.91 (0.88, 0.93)
Surgery 3 0.78 (0.73, 0.82)
Surgery 5 0.64 (0.58, 0.69)
SBRT, Stereotactic body radiation therapy.
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2A. From date of treatment to disease/death/follow-up (years). Disease
free was defined as being alive without disease. The patients with
disease or those who died are counted as disease. Disease-free
survival was defined as the time from date of treatment to date of
cancer recurrence, death or last follow-up
n Mean Minimum Maximum Median
All 609 2.71 0.01 7.44 2.28
Surgery 458 2.91 0.01 7.44 2.67
SBRT 151 2.08 0.05 6.22 1.93
SBRT, Stereotactic body radiation therapy.
2B. Summary of the number of patients with disease and the number of
patients who were disease free at last follow-up
Group
Total
no. patients
Total
no. with
disease
Total no.
disease
free at last
follow-up
Percent disease
free at last
follow-up
SBRT 151 91 60 39.74
Surgery 458 154 304 66.38
609 245 364 59.77
SBRT, Stereotactic body radiation therapy.
2C. Disease-free survival
Group Year Percent disease free 95% Confidence interval
SBRT 1 0.79 (0.72, 0.85)
SBRT 3 0.42 (0.33, 0.51)
SBRT 5 0.19 (0.10, 0.30)
Surgery 1 0.90 (0.87, 0.92)
Surgery 3 0.72 (0.67, 0.76)
Surgery 5 0.56 (0.49, 0.61)
SBRT, Stereotactic body radiation therapy.
3A. From date of treatment to local recurrence/follow-up (years).
Local recurrence is defined as having local recurrence or censored at
any other recurrences or the last follow-up. Local recurrence-free
survival is defined as the time from date of treatment to date of
recurrence or last follow-up
Group n Mean Minimum Maximum Median
All 609 2.56 0.01 7.44 2.08
Surgery 458 2.78 0.01 7.44 2.31
SBRT 151 1.92 0.05 6.22 1.73
For the patients who have local recurrence only
Surgery 12 1.69 0.24 3.90 1.45
SBRT 16 1.57 0.30 4.48 1.37
SBRT, Stereotactic body radiation therapy.
3B. Summary of the number of patients with local recurrence and the
number of patients local recurrence free at last follow-up
Group
Total
no. of
patients
Total no.
with local
recurrence
Total
no. local
recurrence
free at last
follow-up
Percent local
recurrence free at
last follow-up
SBRT 150 16 134 89.33
Surgery 458 12 446 97.38
608 28 580 95.39
SBRT, Stereotactic body radiation therapy.
3C. Local recurrence-free survival
Group Year
Percent local
recurrence free 95% Confidence interval
SBRT 1 0.94 (0.89, 0.97)
SBRT 3 0.85 (0.75, 0.91)
SBRT 5 0.71 (0.44, 0.86)
Surgery 1 0.99 (0.97, 0.99)
Surgery 3 0.97 (0.94, 0.98)
Surgery 5 0.96 (0.92, 0.98)
SBRT, Stereotactic body radiation therapy.
4A. From date of treatment to regional recurrence (years) for the
patients who have local recurrence only. Regional recurrence is
defined as having regional recurrence or censored at any other
recurrences or the last follow-up. Regional recurrence-free survival
is defined as the time from date of treatment to date of recurrence or
last follow-up
Group n Mean Minimum Maximum Median
Surgery 32 1.77 0.41 5.95 1.46
SBRT 15 1.37 0.18 6.22 0.92
SBRT, Stereotactic body radiation therapy.
4B. Summary of the number of patients with regional recurrence and
the number of patients regional recurrence-free at last follow-up
Group
Total
no. of
patients
Total
no. with
regional
recurrence
Total
no. regional
recurrence
free at last
follow-up
Percent
regional
recurrence
free at last
follow-up
SBRT 150 15 135 90.00
Surgery 458 32 426 93.01
608 47 561 92.27
SBRT, Stereotactic body radiation therapy.
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4C. Regional recurrence-free survival
Group Year
Percent regional
recurrence free 95% Confidence interval
SBRT 1 0.93 (0.87, 0.96)
SBRT 3 0.86 (0.76, 0.92)
SBRT 5 0.86 (0.76, 0.92)
Surgery 1 0.99 (0.97, 0.99)
Surgery 3 0.91 (0.88, 0.94)
Surgery 5 0.89 (0.85, 0.93)
SBRT, Stereotactic body radiation therapy.
5A. From date of treatment to distant recurrence (years) for the
patients who have distant recurrence only. Distant recurrence is
defined as having distant recurrence or censored at any other
recurrences or the last follow-up. Distant recurrence-free survival is
defined as the time from date of treatment to date of recurrence or
last follow-up
Group n Mean Minimum Maximum Median
Surgery 58 1.64 0.09 6.50 1.24
SBRT 20 1.63 0.23 3.80 1.49
SBRT, Stereotactic body radiation therapy.
5B. Summary of the number of patients with distant recurrence and
the number of patients distant recurrence free at last follow-up
Group
Total
no. of
patients
Total
no. with distant
recurrence
Total no.
distant
recurrence
free at last
follow-up
Percent distant
recurrence free
at last follow-up
SBRT 150 20 130 86.67
Surgery 458 58 400 87.34
608 78 530 87.17
SBRT, Stereotactic body radiation therapy.
5C. Distant recurrence-free survival
Group Year
Percent distant
recurrence free 95% Confidence interval
SBRT 1 0.94 (0.88, 0.97)
SBRT 3 0.83 (0.72, 0.90)
SBRT 5 0.66 (0.47, 0.80)
Surgery 1 0.94 (0.91, 0.96)
Surgery 3 0.86 (0.82, 0.90)
Surgery 5 0.83 (0.77, 0.87)
SBRT, Stereotactic body radiation therapy.
APPENDIX E3
(1) Overall, (2) disease-free, (3) local-, (4) regional-, and (5)
distant recurrence-free survival are presented for the initial
propensity-matched comparison based on age, tumor stage,
and Adult Comorbidity Evaluation comorbidity score in
patients undergoing surgery (n ¼ 83) versus stereotactic
body radiation therapy (n ¼ 83) for clinical stage I
non–small cell lung cancer (including confidence intervals
for survival analysis).
1A. From date of treatment to follow-up or death (years) for the
matched patients. Median follow-up is 2.34 years
Group n Mean Minimum Maximum Median
All 166 2.86 0.05 7.18 2.34
Surgery 83 3.43 0.08 7.18 3.58
SBRT 83 2.28 0.05 6.32 1.91
SBRT, Stereotactic body radiation therapy.
1B. Summary of the number of deaths and the number of patients alive
at last follow-up. Overall survival is defined from date of treatment to
date of death or the last follow-up
Group
Total
no. of
patients
Total
no. of
deaths
Total no.
alive at last
follow-up
Percent alive at last
follow-up
SBRT 83 45 38 45.78
Surgery 83 31 52 62.65
166 76 90 54.22
SBRT, Stereotactic body radiation therapy.
1C. Overall survival
Group Year Percent alive 95% Confidence interval
SBRT 1 0.83 (0.73, 0.90)
SBRT 3 0.47 (0.35, 0.59)
SBRT 5 0.29 (0.16, 0.44)
Surgery 1 0.88 (0.78, 0.93)
Surgery 3 0.75 (0.63, 0.83)
Surgery 5 0.55 (0.42, 0.67)
SBRT, Stereotactic body radiation therapy.
2A. From date of treatment to disease/death/follow-up (years). Disease
free was defined as being alive without disease. The patients with
disease or those who died are counted as disease. Disease-free
survival was defined as the time from date of treatment to date of
cancer recurrence, death or last follow-up
Group n Mean Minimum Maximum Median
All 166 2.74 0.05 7.18 2.20
Surgery 83 3.30 0.08 7.18 3.38
83 2.17 0.05 6.22 1.89
SBRT, Stereotactic body radiation therapy.
2B. Summary of the number of patients with disease and the number of
patients disease free at last follow-up
Group
Total no. of
patients
Total no.
with disease
Total no.
disease
free at last
follow-up
Percent disease
free at last
follow-up
SBRT 83 52 31 37.35
Surgery 83 38 45 54.22
166 90 76 45.78
SBRT, Stereotactic body radiation therapy.
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2C. Disease-free survival
Group Year Percent disease free 95% Confidence interval
SBRT 1 0.79 (0.69, 0.87)
SBRT 3 0.42 (0.30, 0.54)
SBRT 5 0.21 (0.10, 0.34)
Surgery 1 0.88 (0.78, 0.93)
Surgery 3 0.67 (0.55, 0.76)
Surgery 5 0.47 (0.34, 0.59)
SBRT, Stereotactic body radiation therapy.
3A. From date of treatment to local recurrence/follow-up (years).
Local recurrence is defined as having local recurrence or censored at
any other recurrences or the last follow-up. Local recurrence-free
survival is defined as the time from date of treatment to date of
recurrence or last follow-up
Group n Mean Minimum Maximum Median
All 166 2.56 0.05 7.18 1.98
Surgery 83 3.07 0.08 7.18 2.96
SBRT 83 2.05 0.05 6.22 1.73
For the patients who have local recurrence only
Surgery 2 1.25 0.96 1.53 1.25
SBRT 9 1.56 0.30 4.48 0.90
SBRT, Stereotactic body radiation therapy.
3B. Summary of the number of patients with local recurrence and the
number of patients local recurrence free at last follow-up
Group
Total no. of
patients
Total no.
with local
recurrence
Total no.
local recurrence
free at last
follow-up
Percent local
recurrence
free at last
follow-up
SBRT 83 9 74 89.16
Surgery 83 2 81 97.59
166 11 155 93.37
SBRT, Stereotactic body radiation therapy.
3C. Local recurrence-free survival
Group Year
Percent local
recurrence free 95% Confidence interval
SBRT 1 0.93 (0.84, 0.97)
SBRT 3 0.90 (0.79, 0.95)
SBRT 5 0.71 (0.39, 0.88)
Surgery 1 0.99 (0.90, 0.998)
Surgery 3 0.97 (0.88, 0.99)
Surgery 5 0.97 (0.88, 0.99)
SBRT, Stereotactic body radiation therapy.
4A. From date of treatment to regional recurrence (years) for the
patients who have distant recurrence only. Regional recurrence is
defined as having regional recurrence or censored at any other
recurrences or the last follow-up. Regional recurrence-free survival
is defined as the time from date of treatment to date of recurrence or
last follow-up
Group n Mean Minimum Maximum Median
Surgery 9 1.91 1.21 4.31 1.37
SBRT 8 1.73 0.32 6.22 0.93
SBRT, Stereotactic body radiation therapy.
4B. Summary of the number of patients with regional recurrence and
the number of patients regional recurrence free at last follow-up
Group
Total no. of
patients
Total no. with
regional
recurrence
Total no.
regional recurrence
free at last
follow-up
Percent
regional
recurrence
free at last
follow-up
SBRT 83 8 75 90.36
Surgery 83 9 74 89.16
166 17 149 89.76
SBRT, Stereotactic body radiation therapy.
4C. Regional recurrence-free survival
Group Year
Percent regional
recurrence free 95% Confidence interval
SBRT 1 0.93 (0.84, 0.97)
SBRT 3 0.87 (0.71, 0.94)
SBRT 5 0.87 (0.71, 0.94)
Surgery 1 1.00
Surgery 3 0.89 (0.79, 0.95)
Surgery 5 0.83 (0.69, 0.91)
SBRT, Stereotactic body radiation therapy.
5A. From date of treatment to distant recurrence (years) for the
patients who have distant recurrence only. Distant recurrence is
defined as having distant recurrence or censored at any other
recurrences or the last follow-up. Distant recurrence-free survival is
defined as the time from date of treatment to date of recurrence or
last follow-up
Group n Mean Minimum Maximum Median
Surgery 13 1.65 0.14 3.77 1.80
SBRT 15 1.80 0.23 3.80 1.55
SBRT, Stereotactic body radiation therapy.
5B. Summary of the number of patients with distant recurrence and
the number of patients distant recurrence free at last follow-up
Group
Total no. of
patients
Total no.
with distant
recurrence
Total no.
distant recurrence
free at last
follow-up
Percent distant
recurrence
free at last
follow-up
SBRT 83 15 68 81.93
Surgery 83 13 70 84.34
166 28 138 83.13
SBRT, Stereotactic body radiation therapy.
5C. Distant recurrence-free survival
Group Year
Percent distant
recurrence free 95% Confidence interval
SBRT 1 0.94 (0.85, 0.97)
SBRT 3 0.79 (0.63, 0.89)
SBRT 5 0.58 (0.36, 0.75)
Surgery 1 0.92 (0.84, 0.96)
Surgery 3 0.83 (0.71, 0.90)
Surgery 5 0.78 (0.65, 0.87)
SBRT, Stereotactic body radiation therapy.
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APPENDIX E4
(1) Overall, (2) disease-free, (3) local-, (4) regional-, and (5)
distant recurrence-free survival are presented for the final
propensity-matched comparison based on age, tumor size,
Adult Comorbidity Evaluation comorbidity score, tumor
location (central vs peripheral), and forced expiratory vol-
ume in the first second of expiration (%) in patients under-
going surgery (n ¼ 56) versus stereotactic body radiation
therapy (n¼ 56) for clinical stage I nonsmall cell lung can-
cer (including confidence intervals for survival analysis).
1A. From date of treatment to follow-up or death (years) for the
matched patients. Median follow-up is 2.19 years
Group n Mean Minimum Maximum Median
All 112 2.95 0.09 7.44 2.19
Surgery 56 3.77 0.09 7.44 4.16
SBRT 56 2.13 0.26 6.04 1.88
SBRT, Stereotactic body radiation therapy.
1B. Summary of the number of deaths and the number of patients alive
at last follow-up. Overall survival is defined from date of treatment to
date of death or the last follow-up
Group
Total
no. of
patients
Total
no. of deaths
Total no. alive
at last follow-up
Percent alive at
last follow-up
SBRT 56 26 30 53.57
Surgery 56 24 32 57.14
112 50 62 55.36
SBRT, Stereotactic body radiation therapy.
1C. Overall survival
Group Year Percent alive 95% Confidence interval
SBRT 1 0.83854 0.71263 0.91254
SBRT 2 0.58311 0.43116 0.70764
SBRT 3 0.51629 0.35691 0.65430
SBRT 4 0.46466 0.29405 0.61883
SBRT 5 0.38722 0.19820 0.57340
Surgery 1 0.83636 0.70912 0.91129
Surgery 2 0.74132 0.60220 0.83807
Surgery 3 0.67650 0.53069 0.78578
Surgery 4 0.67650 0.53069 0.78578
Surgery 5 0.58678 0.43679 0.70956
SBRT, Stereotactic body radiation therapy.
2A. From date of treatment to disease/death/follow-up (years). Disease
free was defined as being alive without disease. The patients with
disease or those who died are counted as disease. Disease-free
survival was defined as the time from date of treatment to date of
cancer recurrence, death or last follow-up
Group n Mean Minimum Maximum Median
All 112 2.89 0.09 7.44 2.14
Surgery 56 3.74 0.09 7.44 4.08
SBRT 56 2.04 0.26 6.04 1.82
SBRT, Stereotactic body radiation therapy.
2B. Summary of the number of patients with disease and the number of
patients disease free at last follow-up
Group
Total
no. of
patients
Total
no. with
disease
Total no.
disease free
at last follow-up
Percent disease
free at last follow-up
SBRT 56 30 26 46.43
Surgery 56 25 31 55.36
112 55 57 50.89
SBRT, Stereotactic body radiation therapy.
2C. Disease-free survival
Group Year Percent disease free 95% Confidence interval
SBRT 1 0.78571 0.65362 0.87217
SBRT 2 0.53660 0.38889 0.66345
SBRT 3 0.47137 0.31835 0.61005
SBRT 4 0.37710 0.21541 0.53819
SBRT 5 0.30168 0.13331 0.49032
Surgery 1 0.83636 0.70912 0.91129
Surgery 2 0.74132 0.60220 0.83807
Surgery 3 0.65468 0.50745 0.76756
Surgery 4 0.65468 0.50745 0.76756
Surgery 5 0.56577 0.41620 0.69068
SBRT, Stereotactic body radiation therapy.
3A. From date of treatment to local recurrence/follow-up (years).
Local recurrence is defined as having local recurrence or censored at
any other recurrences or the last follow-up. Local recurrence-free
survival is defined as the time from date of treatment to date of
recurrence or last follow-up
Group n Mean Minimum Maximum Median
All 112 2.78 0.09 7.44 2.14
Surgery 56 3.62 0.09 7.44 3.54
SBRT 56 1.95 0.23 6.04 1.60
For the patients who have local recurrence only
Surgery 3 1.73 0.50 2.37 2.31
SBRT 6 1.95 0.51 4.48 1.16
SBRT, Stereotactic body radiation therapy.
3B. Summary of the number of patients with local recurrence and the
number of patients local recurrence free at last follow-up
Group
Total
no. of
patients
Total
no. with local
recurrence
Total no.
local recurrence
free at last
follow-up
Percent local
recurrence
free at last
follow-up
SBRT 56 6 50 89.29
Surgery 56 3 53 94.64
112 9 103 91.96
SBRT, Stereotactic body radiation therapy.
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3C. Local recurrence-free survival
Group Year
Percent local
recurrence free 95% Confidence interval
SBRT 1 0.93830 0.82069 0.97968
SBRT 2 0.90986 0.77449 0.96569
SBRT 3 0.90986 0.77449 0.96569
SBRT 4 0.80877 0.50295 0.93656
SBRT 5 0.40438 0.01373 0.82601
Surgery 1 0.98077 0.87123 0.99727
Surgery 2 0.98077 0.87123 0.99727
Surgery 3 0.92133 0.77097 0.97452
Surgery 4 0.92133 0.77097 0.97452
Surgery 5 0.92133 0.77097 0.97452
SBRT, Stereotactic body radiation therapy.
4A. From date of treatment to regional recurrence (years) for the
patients who have local recurrence only. Regional recurrence is
defined as having regional recurrence or censored at any other
recurrences or the last follow-up. Regional recurrence-free survival
is defined as the time from date of treatment to date of recurrence or
last follow-up
Group n Mean Minimum Maximum Median
Surgery 3 2.18 0.75 3.31 2.48
SBRT 6 0.90 0.42 1.63 0.91
SBRT, Stereotactic body radiation therapy.
4B. Summary of the number of patients with regional recurrence and
the number of patients regional recurrence free at last follow-up
Group
Total
no. of
patients
Total no.
with regional
recurrence
Total no.
regional
recurrence
free at last
follow-up
Percent regional
recurrence
free at last
follow-up
SBRT 56 6 50 89.29
Surgery 56 3 53 94.64
112 9 103 91.96
SBRT, Stereotactic body radiation therapy.
4C. Regional recurrence-free survival
Group Year
Percent regional
recurrence free 95% Confidence interval
SBRT 1 0.89715 0.77003 0.95592
SBRT 2 0.86511 0.71924 0.93827
SBRT 3 0.86511 0.71924 0.93827
SBRT 4 0.86511 0.71924 0.93827
SBRT 5 0.86511 0.71924 0.93827
Surgery 1 0.97872 0.85840 0.99698
Surgery 2 0.97872 0.85840 0.99698
Surgery 3 0.94610 0.79511 0.98670
Surgery 4 0.91348 0.75036 0.97189
Surgery 5 0.91348 0.75036 0.97189
SBRT, Stereotactic body radiation therapy.
5A. From date of treatment to distant recurrence (years) for the
patients who have distant recurrence only. Distant recurrence is
defined as having distant recurrence or censored at any other
recurrences or the last follow-up. Distant recurrence-free survival is
defined as the time from date of treatment to date of recurrence or
last follow-up
Group n Mean Minimum Maximum Median
Surgery 10 1.54 0.14 5.54 0.69
SBRT 7 1.70 0.23 3.55 1.11
SBRT, Stereotactic body radiation therapy.
5B. Summary of the number of patients with distant recurrence and
the number of patients distant recurrence free at last follow-up
Group
Total no. of
patients
Total no.
with distant
recurrence
Total no.
distant
recurrence
free at last
follow-up
Percent distant
recurrence
free at last
follow-up
SBRT 56 7 49 87.50
Surgery 56 10 46 82.14
112 17 95 84.82
SBRT, Stereotactic body radiation therapy.
5C. Distant recurrence-free survival
Group Year
Percent distant
recurrence free 95% Confidence interval
SBRT 1 0.94505 0.83914 0.98195
SBRT 2 0.91880 0.79472 0.96927
SBRT 3 0.86138 0.66122 0.94759
SBRT 4 0.67833 0.36853 0.85993
SBRT 5 0.67833 0.36853 0.85993
Surgery 1 0.86875 0.74415 0.93521
Surgery 2 0.86875 0.74415 0.93521
Surgery 3 0.84073 0.70348 0.91798
Surgery 4 0.81070 0.66199 0.89874
Surgery 5 0.81070 0.66199 0.89874
SBRT, Stereotactic body radiation therapy.
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FIGURE E1. Overall, disease-free, local-, regional-, and distant-free recurrence survival for the entire cohort of surgical (n ¼ 458) and SBRT (n ¼ 151)
patients with clinical stage I non–small cell lung cancer. SBRT, Stereotactic body radiation therapy.
FIGURE E2. Survival for the entire cohort treated with SBRT with versus without a tissue diagnosis of non–small cell lung cancer.
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FIGURE E3. Overall, disease-free, local-, regional-, and distant-free recurrence survival for the initial propensity-matched comparison based on age,
tumor stage, and Adult Comorbidity Evaluation-27 comorbidity score in patients undergoing surgery (n ¼ 83) versus SBRT (n ¼ 83) for clinical stage I
non–small cell lung cancer. SBRT, Stereotactic body radiation therapy.
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